Involvement of HMGB1 in Resistance to Tumor Vessel-Targeted, Monoclonal Antibody-Based Immunotherapy
High mobility group box 1 (HMGB1) is a member of the “danger associated molecular patterns” (DAMPs) than can localize in various compartments of the cell (from the nucleus to the cell surface) and subserve different functions accordingly. HMGB1 is implicated in maintenance of genomic stability, auto...
Saved in:
Main Authors: | Vito Pistoia, Annalisa Pezzolo |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2016-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2016/3142365 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Anti-HMGB1 Monoclonal Antibody Ameliorates Immunosuppression after Peripheral Tissue Trauma: Attenuated T-Lymphocyte Response and Increased Splenic CD11b+Gr-1+ Myeloid-Derived Suppressor Cells Require HMGB1
by: Xiangcai Ruan, et al.
Published: (2015-01-01) -
Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies
by: Yizhou Zhang, et al.
Published: (2024-12-01) -
Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
by: Coraline Radermecker, et al.
Published: (2021-03-01) -
Editorial: Antiviral monoclonal antibody therapies
by: Catalina Florez, et al.
Published: (2024-10-01) -
Role of Monoclonal Antibodies in the Treatment of Asthma
by: Paul M O’Byrne
Published: (2013-01-01)